U.S. Markets closed

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.175+0.00 (+1.45%)
At close: 3:57PM EDT
People also watch

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States

Full Time Employees15

Key Executives

Ms. Linda F. Powers J.D.Chairperson, Chief Exec. Officer, Pres and Chief Financial Officer502kN/A61
Dr. Alton L. Boynton Ph.D.Founder, Chief Scientific Officer, Sec. and Director325kN/A72
Dr. Marnix L. Bosch Ph.D., MBAChief Technical Officer375kN/A58
Mr. Leslie J. GoldmanSr. VP of Bus. Devel.375kN/A72
Dr. Anthony E. Maida III, MA, MBA, Ph.D.Sr. VP of Clinical ResearchN/AN/A65
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate Governance

Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.